vs
Side-by-side financial comparison of Grocery Outlet Holding Corp. (GO) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $1.2B, roughly 2.0× Grocery Outlet Holding Corp.). Zoetis runs the higher net margin — 25.3% vs -18.5%, a 43.8% gap on every dollar of revenue. On growth, Grocery Outlet Holding Corp. posted the faster year-over-year revenue change (10.7% vs 3.0%). Over the past eight quarters, Grocery Outlet Holding Corp.'s revenue compounded faster (8.3% CAGR vs 4.4%).
Grocery Outlet Holding Corp. is an American discount closeout retailer consisting exclusively of supermarket locations that offer discounted, overstocked, and closeout products from name-brand and private-label suppliers. The company has stores in California, Oregon, Washington, Idaho, Nevada, Maryland, Pennsylvania, New Jersey, Ohio, and Delaware.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
GO vs ZTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $2.4B |
| Net Profit | $-224.9M | $603.0M |
| Gross Margin | 29.7% | 70.2% |
| Operating Margin | — | 31.9% |
| Net Margin | -18.5% | 25.3% |
| Revenue YoY | 10.7% | 3.0% |
| Net Profit YoY | -669.9% | 3.8% |
| EPS (diluted) | $-2.22 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.2B | — | ||
| Q4 25 | — | $2.4B | ||
| Q3 25 | $1.2B | $2.4B | ||
| Q2 25 | $1.2B | $2.5B | ||
| Q1 25 | $1.1B | $2.2B | ||
| Q4 24 | $1.1B | $2.3B | ||
| Q3 24 | $1.1B | $2.4B | ||
| Q2 24 | $1.1B | $2.4B |
| Q1 26 | $-224.9M | — | ||
| Q4 25 | — | $603.0M | ||
| Q3 25 | $11.6M | $721.0M | ||
| Q2 25 | $5.0M | $718.0M | ||
| Q1 25 | $-23.3M | $631.0M | ||
| Q4 24 | $2.3M | $581.0M | ||
| Q3 24 | $24.2M | $682.0M | ||
| Q2 24 | $14.0M | $624.0M |
| Q1 26 | 29.7% | — | ||
| Q4 25 | — | 70.2% | ||
| Q3 25 | 30.4% | 71.5% | ||
| Q2 25 | 30.6% | 73.6% | ||
| Q1 25 | 30.4% | 72.0% | ||
| Q4 24 | 29.5% | 69.5% | ||
| Q3 24 | 31.1% | 70.6% | ||
| Q2 24 | 30.9% | 71.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 31.9% | ||
| Q3 25 | 2.0% | 37.0% | ||
| Q2 25 | 1.1% | 36.7% | ||
| Q1 25 | -2.0% | 36.5% | ||
| Q4 24 | 1.0% | 31.6% | ||
| Q3 24 | 3.6% | 36.6% | ||
| Q2 24 | 2.3% | 33.0% |
| Q1 26 | -18.5% | — | ||
| Q4 25 | — | 25.3% | ||
| Q3 25 | 1.0% | 30.0% | ||
| Q2 25 | 0.4% | 29.2% | ||
| Q1 25 | -2.1% | 28.4% | ||
| Q4 24 | 0.2% | 25.1% | ||
| Q3 24 | 2.2% | 28.6% | ||
| Q2 24 | 1.2% | 26.4% |
| Q1 26 | $-2.22 | — | ||
| Q4 25 | — | $1.37 | ||
| Q3 25 | $0.12 | $1.63 | ||
| Q2 25 | $0.05 | $1.61 | ||
| Q1 25 | $-0.24 | $1.41 | ||
| Q4 24 | $0.03 | $1.29 | ||
| Q3 24 | $0.24 | $1.50 | ||
| Q2 24 | $0.14 | $1.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $69.6M | — |
| Total DebtLower is stronger | $15.0M | — |
| Stockholders' EquityBook value | $983.7M | $3.3B |
| Total Assets | $3.1B | $15.5B |
| Debt / EquityLower = less leverage | 0.02× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $69.6M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $52.1M | $2.1B | ||
| Q2 25 | $55.2M | $1.4B | ||
| Q1 25 | $50.9M | $1.7B | ||
| Q4 24 | $62.8M | $2.0B | ||
| Q3 24 | $68.7M | $1.7B | ||
| Q2 24 | $67.1M | $1.6B |
| Q1 26 | $15.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $500.3M | — | ||
| Q2 25 | $473.9M | — | ||
| Q1 25 | $475.7M | — | ||
| Q4 24 | $477.5M | — | ||
| Q3 24 | $429.3M | — | ||
| Q2 24 | $379.2M | — |
| Q1 26 | $983.7M | — | ||
| Q4 25 | — | $3.3B | ||
| Q3 25 | $1.2B | $5.4B | ||
| Q2 25 | $1.2B | $5.0B | ||
| Q1 25 | $1.2B | $4.7B | ||
| Q4 24 | $1.2B | $4.8B | ||
| Q3 24 | $1.2B | $5.2B | ||
| Q2 24 | $1.2B | $5.0B |
| Q1 26 | $3.1B | — | ||
| Q4 25 | — | $15.5B | ||
| Q3 25 | $3.4B | $15.2B | ||
| Q2 25 | $3.3B | $14.5B | ||
| Q1 25 | $3.3B | $14.1B | ||
| Q4 24 | $3.2B | $14.2B | ||
| Q3 24 | $3.1B | $14.4B | ||
| Q2 24 | $3.1B | $14.2B |
| Q1 26 | 0.02× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.42× | — | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | 0.40× | — | ||
| Q4 24 | 0.40× | — | ||
| Q3 24 | 0.35× | — | ||
| Q2 24 | 0.31× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $222.1M | $893.0M |
| Free Cash FlowOCF − Capex | — | $732.0M |
| FCF MarginFCF / Revenue | — | 30.7% |
| Capex IntensityCapex / Revenue | — | 6.7% |
| Cash ConversionOCF / Net Profit | — | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | — | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $222.1M | — | ||
| Q4 25 | — | $893.0M | ||
| Q3 25 | $17.3M | $938.0M | ||
| Q2 25 | $73.6M | $486.0M | ||
| Q1 25 | $58.9M | $587.0M | ||
| Q4 24 | $39.5M | $905.0M | ||
| Q3 24 | $23.0M | $951.0M | ||
| Q2 24 | $41.6M | $502.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $732.0M | ||
| Q3 25 | $-21.6M | $805.0M | ||
| Q2 25 | $14.4M | $308.0M | ||
| Q1 25 | $-1.5M | $438.0M | ||
| Q4 24 | $-19.6M | $689.0M | ||
| Q3 24 | $-19.3M | $784.0M | ||
| Q2 24 | $2.7M | $370.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 30.7% | ||
| Q3 25 | -1.8% | 33.5% | ||
| Q2 25 | 1.2% | 12.5% | ||
| Q1 25 | -0.1% | 19.7% | ||
| Q4 24 | -1.8% | 29.7% | ||
| Q3 24 | -1.7% | 32.8% | ||
| Q2 24 | 0.2% | 15.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 6.7% | ||
| Q3 25 | 3.3% | 5.5% | ||
| Q2 25 | 5.0% | 7.2% | ||
| Q1 25 | 5.4% | 6.7% | ||
| Q4 24 | 5.4% | 9.3% | ||
| Q3 24 | 3.8% | 7.0% | ||
| Q2 24 | 3.4% | 5.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.48× | ||
| Q3 25 | 1.49× | 1.30× | ||
| Q2 25 | 14.84× | 0.68× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | 17.09× | 1.56× | ||
| Q3 24 | 0.95× | 1.39× | ||
| Q2 24 | 2.97× | 0.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GO
Segment breakdown not available.
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
